Sign in
4

Changes in Ownership

Xenon Pharmaceuticals Inc. Filed Acc 0000950170-24-028795

EVP, Strategy & Innovation sold 7,137 shares at an average $46.28 ($330,290)

  • EVP, Strategy & Innovation acquired 8,641 shares (option exercise)
  • EVP, Strategy & Innovation gave up 1,504 shares (to pay taxes)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Option exercise +1,234 $9.85 $12,155 9,632 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Shares withheld for taxes −215 $45.96 $9,881 9,417 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Option exercise +7,407 $9.85 $72,959 16,824 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Shares withheld for taxes −1,289 $45.96 $59,242 15,535 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Sale −1,019 $46.15 $47,027 14,516 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Sale −6,118 $46.30 $283,263 8,398 D
Derivatives
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Option exercise · Stock Option (Right to Buy) −1,234 0 D
ROBIN SHERRINGTON EVP, Strategy & Innovation 2024-03-07 Option exercise · Stock Option (Right to Buy) −7,407 0 D
Open-market sales · 7,137 sh · avg $46.28 · $330,290
Loading xslF345X05/ownership.xml…